• In late February 2026, the Centers for Medicare & Medicaid Services confirmed it will assign specific C-codes for Inspire Medical Systems’ Inspire V device in an upcoming outpatient coding update, resolving longstanding reimbursement uncertainties for its hypoglossal nerve stimulation therapy for obstructive sleep apnea.
• This coding clarification is important because it simplifies hospital and ambulatory surgery center billing, may improve payment predictability, and could make it easier for providers to adopt Inspire’s neurostimulation treatment.
• We’ll now examine how this new CMS coding clarity for Inspire V affects Inspire Medical Systems’ investment narrative and long-term adoption thesis.

We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Inspire Medical Systems Investment Narrative Recap

To own Inspire Medical Systems, you need to believe its hypoglossal nerve stimulation can remain a preferred option for obstructive sleep apnea while the Inspire V rollout stabilizes. The clearest near term catalyst is restoring procedure growth as centers transition to Inspire V, and the biggest risk remains execution around that transition and reimbursement. The new CMS C codes directly reduce one key source of uncertainty by improving billing clarity, which supports but does not eliminate that execution risk.

The CMS decision to assign specific C codes for Inspire V is the announcement that most directly ties into this story. It addresses prior coding and reimbursement ambiguity that had already fed into lower 2026 revenue guidance, and it could help re align hospital and ASC economics with the company’s growth ambitions. How effectively Inspire converts this coding win into higher, more predictable procedure volumes now sits at the center of the near term catalyst path.

Yet against this clearer coding backdrop, investors still need to weigh the risk that payer and regulatory shifts could pressure margins and coverage in ways that are important to understand...

Inspire Medical Systems’ narrative projects $1.3 billion in revenue and $103.6 million in earnings by 2028.

Uncover how Inspire Medical Systems' forecasts yield a $124.40 fair value, a 92% upside to its current price.

Exploring Other Perspectives

Before this CMS news, the most optimistic analysts were assuming Inspire could reach about US$1.4 billion in revenue and US$157 million in earnings by 2028, so you may find their far more upbeat view on reimbursement and volume growth very different from the more cautious concerns about regulatory pressure and coverage that you have just read.

Explore 9 other fair value estimates on Inspire Medical Systems - why the stock might be worth over 4x more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Inspire Medical Systems research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Inspire Medical Systems research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Inspire Medical Systems' overall financial health at a glance.

Interested In Other Possibilities?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Uncover the next big thing with 30 elite penny stocks that balance risk and reward.
• Find 45 companies with promising cash flow potential yet trading below their fair value.
• This technology could replace computers: discover 22 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.